SEC Form 4 · accession 0001104659-17-000631
Cardiff Oncology, Inc. · CRDF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Paul Billings
Director
Period of report
Jan 2, 2017
Accepted (ET)
Jan 4, 2017 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001213037
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jan 2, 2017 | A | 16,667 | A | — | — | Common Stock | 16,667 | 16,667 | D |
Explanation of responses
- F1Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock.
- F2The RSUs shall vest on January 2, 2018.